INKT stock forecast, quote, news & analysis
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases... Show more
Why MiNK Therapeutics (INKT) Stock Is Down -12.4% in the Last 30 Days
Key Takeaways
- MiNK Therapeutics (INKT) shares declined roughly 12.4% over the last 30 days, falling from a closing price of $12.13 on September 28 to $10.63 on October 27.
- The pullback followed a September rally that carried the stock to a recent peak near $12.73 in early October before momentum reversed.
- Over the most recent quarter, the stock is essentially flat, up about 0.9%, reflecting a volatile, range-bound trading pattern.
- MiNK remains a clinical-stage biotech with no approved products; its lead candidate, agenT-797, is an off-the-shelf iNKT cell therapy in a randomized Phase 2 trial for acute lung injury and critical illness.
- Low trading liquidity and a micro-cap valuation make INKT susceptible to sharp, sentiment-driven swings even without a single company-specific announcement.
- Investors can review detailed Price Targets, Earnings, and Forecast data for INKT on dedicated pages.
- For additional market intelligence, explore Trending AI Robots.
MiNK Therapeutics (INKT) Company Overview and Market Position
MiNK Therapeutics is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies designed to restore immune balance across cancer and immune-mediated diseases. Its lead program, agenT-797, is an unmodified iNKT cell therapy that can be administered without HLA matching or lymphodepleting chemotherapy, positioning it as a potentially scalable and rapidly deployable treatment.
The company, which was spun out of Agenus, is advancing agenT-797 in severe acute lung injury and acute respiratory distress syndrome (ARDS), as well as in solid tumors and graft-versus-host disease (GvHD). Investors follow INKT for its differentiated cell-therapy platform, non-dilutive funding strategy, and a pipeline of catalysts tied to clinical data readouts, though the company remains pre-revenue and heavily dependent on external financing.
MiNK Therapeutics (INKT) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, INKT declined from a closing price of $12.13 on September 28 to $10.63 on October 27, a drop of approximately 12.4%. The decline was concentrated in the first half of October, when the stock pulled back from its early-October high near $12.73 and briefly traded below $9.40 before stabilizing in the low-to-mid $10 range.
The broader quarterly picture is more balanced. Three months earlier, on July 28, the stock closed at $10.54, meaning the quarter's net change is a modest gain of roughly 0.9%. In between, INKT rallied through August and September before giving back most of those gains, underscoring a choppy, range-bound environment rather than a sustained directional trend.
What Drove INKT Stock Price in the Last 30 Days
The 30-day decline does not appear tied to a single company-specific disclosure. Instead, the move reflects a combination of profit-taking after a September run-up, thin trading liquidity, and broader risk sentiment surrounding small-cap clinical-stage biotechs. INKT trades on modest daily volume, and micro-cap names with concentrated clinical catalysts can experience outsized swings as short-term traders lock in gains or reposition.
During the period, the company's fundamental story remained centered on its agenT-797 program, including the randomized Phase 2 trial in acute lung injury and critical illness initiated earlier in 2026, with preliminary data expected in the second half of the year. The absence of a fresh catalyst in the last 30 days likely allowed technical and liquidity factors to dominate price action.
What Drove INKT Stock Performance Over the Last Quarter
Over the most recent quarter, INKT moved broadly sideways, recovering from a late-July low before peaking in early October and retreating again. The multi-month narrative has been driven by MiNK's transition toward randomized clinical validation of agenT-797, capital-efficient expansion through non-dilutive collaborations such as the C-Further partnership for a PRAME-targeted pediatric oncology program, and disciplined cost management aimed at extending its cash runway.
Earlier in 2026, the stock traded materially higher, briefly reaching the mid-teens in March following clinical and partnership announcements. The subsequent drift reflects the market's wait-and-see posture ahead of randomized Phase 2 data, combined with the inherent financing risk that accompanies a pre-revenue, clinical-stage company.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots drawn from a much larger universe. Tickeron offers hundreds of AI trading bots that collectively trade thousands of tickers, but only the top-performing and most relevant bots appear in this section. These bots vary widely in strategy, holding timeframe, and performance metrics, giving traders a way to compare different automated approaches across different market conditions. For investors seeking a systematic, data-driven complement to manual analysis, exploring the Trending AI Robots page can provide additional perspective on how automated strategies are currently positioning across the market.
INKT Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most important catalysts for INKT include preliminary data from the randomized Phase 2 trial of agenT-797 in acute lung injury and ARDS, which the company has guided for the second half of 2026. Progress on U.S. site activation and FDA feedback on trial design will also be closely watched. Additional watch items include updated financial results, cash runway and any financing activities, advancement of the C-Further pediatric oncology collaboration, and broader sector sentiment toward clinical-stage cell-therapy companies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
INKT in upward trend: price may jump up because it broke its lower Bollinger Band on October 07, 2026
INKT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 34 cases where INKT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where INKT's RSI Oscillator exited the oversold zone, 19 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 67 cases where INKT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for INKT just turned positive on November 11, 2026. Looking at past instances where INKT's MACD turned positive, the stock continued to rise in 40 of 53 cases over the following month. The odds of a continued upward trend are 75%.
Following a +2.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where INKT advanced for three days, in 167 of 217 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INKT as a result. In 101 of 111 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
INKT moved below its 50-day moving average on October 07, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for INKT crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.
The 50-day moving average for INKT moved below the 200-day moving average on November 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INKT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for INKT entered a downward trend on October 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-3.692) is normal, around the industry mean (3.498). P/E Ratio (-4.283) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 39 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 70 (best 1 - 100 worst), indicating slightly worse than average price growth. INKT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INKT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology